Associated Papers
Mutational landscape of lung adenocarcinoma in Czechia.
Ambrozkiewicz F et al.
Cancer Treatment and Research Communications, 2026
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Clinical and genomic features of Lynch syndrome differ by tumor site and disease spectrum.
Li S et al.
Nature Communications, 2025
Challenges associated with the treatment of E709K and L858R double mutation in lung adenocarcinoma: A case report and literature review.
Song J et al.
Oncology Letters, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancer.
Huang L et al.
Cancer, 2025
Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing.
Mamesaya N et al.
International Journal of Clinical Oncology, 2025
The effectiveness of sequential afatinib and furmonertinib in an advanced lung adenocarcinoma with rare compound EGFR mutation (L833V/H835L).
Pan Y et al.
Anti-cancer Drugs, 2025
Rare exon 18 G719A and exon 21 L833V compound EGFR mutations show favorable response to Third-Generation TKI Furmonertinib: A case report and literature review.
Yuejian et al.
Investigational New Drugs, 2025
Multi-gene panel sequencing reveals the relationship between driver gene mutation and clinical characteristics in lung adenocarcinoma.
Li J et al.
Discover Oncology, 2025
Comprehensive characterization of early-onset lung cancer, in Chinese young adults.
Tian Y et al.
Nature Communications, 2025
Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital.
Kim JW et al.
Scientific Reports, 2025
High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study.
Chen H et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2025
Treatment of advanced lung adenocarcinoma with EGFR L833V/H835L compound mutations using furmonertinib: two case reports and literature review.
Wang S et al.
Frontiers in Medicine, 2025
Clinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next-Generation Sequencing With Insufficient Tumor Samples.
Sun Y et al.
Journal of Clinical Laboratory Analysis, 2024
A Case Report of Concurrent Epidermal Growth Factor Receptor (EGFR) Exon 18 (G719A) and Exon 21 (L833_V834delinsFL) Mutations and Treatment Challenges.
Hussain M et al.
Cureus, 2024
Oncogene-Driven Non-Small Cell Lung Cancers in Patients with a History of Smoking Lack Smoking-Induced Mutations.
Huang CY et al.
Cancer Research, 2024
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO).
Pizzutilo EG et al.
Esmo Open, 2024
Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
Li T et al.
Cancer Medicine, 2024
An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report.
Boukansa S et al.
Journal of Medical Case Reports, 2024
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
Okuma Y et al.
Jama Oncology, 2024
Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.
Wang HY et al.
Jco Precision Oncology, 2024
An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development.
Wang Q et al.
Journal of Cancer, 2024
[A Rare Case of Lung Adenocarcinoma with EGFR L833V/H835L Co-mutation and Literature Review].
Miao Y et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2023
Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant ( L833V / H835L ) lung adenocarcinoma patient: a case report.
Luo Z et al.
Anti-cancer Drugs, 2023
Virtual Screening of Different Subclasses of Lignans with Anticancer Potential and Based on Genetic Profile.
Maia MDS et al.
Molecules (basel, Switzerland), 2023
A pilot study of on-site evaluation as external quality assessment for ISO 15189 accreditation of laboratories performing next-generation sequencing oncology tests.
Ravzanaadii M et al.
Journal of Clinical Laboratory Analysis, 2023
All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations.
Ullas B et al.
Journal of Cancer Research and Clinical Oncology, 2023
The Unique Genetic Mutation Characteristics Based on Large Panel Next-Generation Sequencing (NGS) Detection in Multiple Primary Lung Cancers (MPLC) Patients.
Liang Z et al.
Discovery Medicine, 2023
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study.
Ji J et al.
Jto Clinical and Research Reports, 2023
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report.
Pan H et al.
Frontiers in Oncology, 2023
Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review.
Li L et al.
Frontiers in Pharmacology, 2023
Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma.
Liu X et al.
Frontiers in Oncology, 2023
Prognostic and predictive role of liquid biopsy in lung cancer patients.
Goksel T et al.
Frontiers in Oncology, 2023
Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study.
Gu L et al.
Journal of Clinical Medicine, 2022
A L833V/H835L EGFR variant lung adenocarcinoma with skin metastasis: A case report and literature review.
Yang X et al.
Heliyon, 2022
Multiple mutations in the EGFR gene in lung cancer: a systematic review.
Castañeda-González JP et al.
Translational Lung Cancer Research, 2022
Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer.
Lyu D et al.
Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu, 2022
A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report.
Zhou T et al.
Medicine, 2022
Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report.
Zhou B et al.
Medicine, 2022
Unique characteristics of G719X and S768I compound double mutations of epidermal growth factor receptor (EGFR) gene in lung cancer of coal-producing areas of East Yunnan in Southwestern China.
Wang JL et al.
Genes and Environment : the Official Journal of the Japanese Environmental Mutagen Society, 2022
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Next generation sequencing for detection of EGFR alterations in NSCLC: is more better?
Batra U et al.
Journal of Clinical Pathology, 2022
Investigation of EGFR mutations in non-small cell lung cancer usually undetectable by PCR methods.
Matsubara T et al.
Molecular and Clinical Oncology, 2022